Cytel Acquires Laiya Consulting

Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. The deal follows the recent release of Cytel’s East Alloy platform for easy access to verified Bayesian tools, and marks the latest step in Cytel’s commitment aiming to broadenin industry access to clinical trial design methods.

"As we look to make the benefits of sophisticated Bayesian methods ever more accessible to drug developers, we’re taking strategic leaps to both bolster our core offerings and streamline their delivery to the market," said Yannis Jemiai, Chief Scientific Officer at Cytel. "Partnering with Laiya allows us to smoothly feed into our broad Bayesian software capabilities with ever greater levels of statistical innovation and expertise. We look forward to welcoming Dr Yuan Ji and his colleagues to the team."

"Bayesian approaches, when applied correctly, open an abundance of opportunity in clinical development, evidenced by our own and Cytel’s extensive work in this field," said Dr Yuan Ji, Co-founder of Laiya Consulting. "Merging with Cytel means unifying two rich sources of statistical proficiency to continue setting new standards for Bayesian design, which will ultimately help us to further enable drug developers to profitably solve the most intricate clinical challenges."

Read the full release, here.​